Speaking of getting the word out... I tried doing my part by messaging, both, Third Rock Investments and Baker Brothers last Friday.
Daniel Lynch of Third Rock is on the board of Proclara, which has a drug in development that targets protein misfolding and was articled in FierceBiotech. I wrote to advise him about Anavex and that its science may well be better and why. A similar message was sent to Felix Baker and others at Baker Bros.
Hopefully, each company will look into Anavex and initiate a position.